About Sitari PharmaceuticalsSitari Pharmaceuticals, Inc. develops treatments for multiple disease indications such as celiac disease. The company offers targeted inhibitors of Transglutaminase 2 (TG2) with the potential to suppress the autoimmune response that results in intestinal inflammation and cell pathogenesis in celiac patients. Sitari Pharmaceuticals, Inc. was founded in 2013 and is based in San Diego, California.
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.